The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where consensus estimates seem disconnected from reality.

Two Stocks to Sell:

Amtech (ASYS)

Consensus Price Target: $6 (33.3% implied return)

Focusing on the silicon carbide and power semiconductor sectors, Amtech Systems (NASDAQ: ASYS) produces the machinery and related chemicals needed for manufacturing semiconductors.

Why Do We Avoid ASYS?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 7.9% annually over the last two years
2. Historical operating margin losses point to an inefficient cost structure
3. Push for growth has led to negative returns on capital, signaling value destruction, and its decreasing returns suggest its historical profit centers are aging

At $4.50 per share, Amtech trades at 17x forward EV-to-EBITDA. To fully understand why you should be careful with ASYS, check out our full research report (it’s free).

Bark (BARK)

Consensus Price Target: $2.33 (159% implied return)

Making a name for itself with the BarkBox, Bark (NYSE: BARK) specializes in subscription-based, personalized pet products.

Why Should You Dump BARK?

1. Sales tumbled by 4.9% annually over the last two years, showing consumer trends are working against its favor
2. Poor expense management has led to operating margin losses
3. Cash burn makes us question whether it can achieve sustainable long-term growth

Bark is trading at $0.90 per share, or 45.3x forward P/E. Check out our free in-depth research report to learn more about why BARK doesn’t pass our bar.

One Stock to Buy:

Molina Healthcare (MOH)

Consensus Price Target: $325.22 (49.2% implied return)

Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE: MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.

Why Do We Love MOH?

1. Annual revenue growth of 19.4% over the past five years was outstanding, reflecting market share gains this cycle
2. Large revenue base of $41.87 billion gives it power over healthcare providers and plan holders
3. Earnings per share grew by 14.5% annually over the last five years and trumped its peers

Molina Healthcare’s stock price of $218 implies a valuation ratio of 8.4x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.

Stocks We Like Even More

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.